Cargando…

Novel Oral CGRP Receptor Antagonist Atogepant in the Prevention of Migraine

Advancements in molecular biology and neuroscience have uncovered calcitonin gene-related peptide (CGRP), a neuropeptide consisting of thirty-seven amino acids that plays a crucial role in migraine pathogenesis. CGRP receptor antagonist or gepant is an oral medication that can impede the nociceptive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chowdhury, Selia, Dave, Tirth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Applied Systems srl 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411686/ https://www.ncbi.nlm.nih.gov/pubmed/37564925 http://dx.doi.org/10.15190/d.2023.6

Ejemplares similares

Atogepant for the prevention of episodic migraine in adults
por: Switzer, Maranda Paige, et al.
Publicado: (2022)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations
por: Cohen, Fred, et al.
Publicado: (2022)

CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine
por: Capi, Matilde, et al.
Publicado: (2021)

Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy
por: Holland, Philip R., et al.
Publicado: (2018)

Calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraines in adults
por: Ocheretyaner, Eric R, et al.
Publicado: (2022)

Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor
por: Blumenfeld, Andrew, et al.
Publicado: (2021)

Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety
por: Lattanzi, Simona, et al.
Publicado: (2022)

A CGRP receptor antagonist peptide formulated for nasal administration to treat migraine
por: von Mentzer, Bengt, et al.
Publicado: (2020)

Serotonin and CGRP in Migraine
por: Aggarwal, Milan, et al.
Publicado: (2012)

CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009)

CGRP and migraine
por: Cauchi, M., et al.
Publicado: (2016)

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial
por: Schwedt, Todd J, et al.
Publicado: (2021)

The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials
por: Tao, Xinyu, et al.
Publicado: (2022)

Gender aspects of CGRP in migraine
por: Labastida-Ramírez, Alejandro, et al.
Publicado: (2017)

CGRP receptors and TRP channels in migraine
por: Geppetti, Pierangelo, et al.
Publicado: (2015)

CGRP and the Trigeminal System in Migraine
por: Iyengar, Smriti, et al.
Publicado: (2019)

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial
por: Lipton, Richard B., et al.
Publicado: (2023)

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

CGRP and migraine: neurogenic inflammation revisited
por: Geppetti, P., et al.
Publicado: (2005)

Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial
por: Ashina, Messoud, et al.
Publicado: (2023)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy
por: Mullin, Kathleen, et al.
Publicado: (2020)

New CGRP Antagonists
por: Doods, H. N., et al.
Publicado: (2001)

Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale
por: Cohen, Fred, et al.
Publicado: (2022)

Future targets for migraine treatment beyond CGRP
por: Al-Hassany, Linda, et al.
Publicado: (2023)

Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments
por: Nissan, George R., et al.
Publicado: (2022)

Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial
por: Lipton, Richard B., et al.
Publicado: (2022)

Lipidated Calcitonin Gene-Related Peptide (CGRP) Peptide Antagonists Retain CGRP Receptor Activity and Attenuate CGRP Action In Vivo
por: Jamaluddin, Aqfan, et al.
Publicado: (2022)

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
por: Tso, Amy R., et al.
Publicado: (2017)

Serum CGRP in migraine patients using erenumab as preventive treatment
por: de Vries Lentsch, Simone, et al.
Publicado: (2022)

Shared and independent roles of CGRP and PACAP in migraine pathophysiology
por: Kuburas, Adisa, et al.
Publicado: (2023)

Nutrition and Calcitonin Gene Related Peptide (CGRP) in Migraine
por: Fila, Michal, et al.
Publicado: (2023)

CGRP and Migraine: What Have We Learned From Measuring CGRP in Migraine Patients So Far?
por: Kamm, Katharina
Publicado: (2022)

A Novel Nonpeptide CGRP Receptor Antagonist, ‘Compound 1’ (WO98/11128) Is a High Affinity Competitive Antagonist at the CGRP1 Receptor in Human Coronary Arteries
por: Hasbak, P., et al.
Publicado: (2001)

Characterization of transit rates in the large intestine of mice following treatment with a CGRP antibody, CGRP receptor antibody, and small molecule CGRP receptor antagonists
por: Johnson, Kirk W., et al.
Publicado: (2022)

Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy
por: Scuteri, Damiana, et al.
Publicado: (2021)

CGRP as a Migraine Inducing Substance
por: Olesen, J., et al.
Publicado: (2001)

Dural Immune Cells, CGRP, and Migraine
por: Balcziak, Louis K., et al.
Publicado: (2022)

CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
por: Favoni, Valentina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i5tn44d26v5f2uot4ok8t13usr